GL Ventures, the venture capital (VC) arm of Hillhouse Capital, has led a Series D funding of nearly 600 million yuan ($91.6 million) in Coyote Bioscience, a Chinese molecular diagnostics firm that specialises in point-of-care testing (POCT).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
